Terms: = Prostate cancer AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12
62 results:
1. Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across cancer Types.
Kasi PM; Lee JK; Pasquina LW; Decker B; Vanden Borre P; Pavlick DC; Allen JM; Parachoniak C; Quintanilha JCF; Graf RP; Schrock AB; Oxnard GR; Lovly CM; Tukachinsky H; Subbiah V
Clin Cancer Res; 2024 Feb; 30(4):836-848. PubMed ID: 38060240
[TBL] [Abstract] [Full Text] [Related]
2. Amplification of Wild-Type
Gandhi MM; Ricciuti B; Harada G; Repetto M; Gildenberg MS; Singh A; Li YY; Gagné A; Wang X; Aizer A; Fitzgerald K; Nishino M; Alessi J; Pecci F; Di Federico A; Fisch A; Drilon A; Nardi V; Sholl L; Awad MM; Rotow J
JCO Precis Oncol; 2023 Sep; 7():e2300295. PubMed ID: 37972337
[TBL] [Abstract] [Full Text] [Related]
3. Reirradiation salvage radiotherapy for recurrent prostate cancer after primary low-dose brachytherapy.
Muñoz Muñoz Ó; Gomis Sellés E; Delgado León BD; Mateos Perez JC; Baeza Trujillo M; Perucha Ortega M; López Guerra JL; Cabrera Roldán P
Clin Transl Oncol; 2024 Apr; 26(4):872-879. PubMed ID: 37672205
[TBL] [Abstract] [Full Text] [Related]
4. Growth differentiation factor 15 (GDF-15) in endocrinology.
Iglesias P; Silvestre RA; Díez JJ
Endocrine; 2023 Sep; 81(3):419-431. PubMed ID: 37129758
[TBL] [Abstract] [Full Text] [Related]
5. ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer.
Bae SY; Bergom HE; Day A; Greene JT; Sychev ZE; Larson G; Corey E; Plymate SR; Freedman TS; Hwang JH; Drake JM
Front Endocrinol (Lausanne); 2023; 14():1093332. PubMed ID: 37065756
[TBL] [Abstract] [Full Text] [Related]
6. Introducing AgNPs-VB
Liu Z; Wang J; Cui C; Zheng L; Hu L
Talanta; 2023 Jan; 252():123886. PubMed ID: 36055078
[TBL] [Abstract] [Full Text] [Related]
7. Identification of fusions with potential clinical significance in melanoma.
Moran JMT; Le LP; Nardi V; Golas J; Farahani AA; Signorelli S; Onozato ML; Foreman RK; Duncan LM; Lawrence DP; Lennerz JK; Dias-Santagata D; Hoang MP
Mod Pathol; 2022 Dec; 35(12):1837-1847. PubMed ID: 35871080
[TBL] [Abstract] [Full Text] [Related]
8. Supported progressive resistance exercise training to counter the adverse side effects of robot-assisted radical prostatectomy: a randomised controlled trial.
Ashton RE; Aning JJ; Tew GA; Robson WA; Saxton JM
Support Care Cancer; 2021 Aug; 29(8):4595-4605. PubMed ID: 33483790
[TBL] [Abstract] [Full Text] [Related]
9. Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.
Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Lin DW; Corey E; Nelson PS; Morrissey C
PLoS One; 2021; 16(1):e0245602. PubMed ID: 33471819
[TBL] [Abstract] [Full Text] [Related]
10. CHEK2 Mutation in Patient with Multiple Endocrine Glands Tumors. Case Report.
Szeliga A; Pralat A; Witczak W; Podfigurna A; Wojtyla C; Kostrzak A; Meczekalski B
Int J Environ Res Public Health; 2020 Jun; 17(12):. PubMed ID: 32570972
[TBL] [Abstract] [Full Text] [Related]
11. Targeting ret Kinase in Neuroendocrine prostate cancer.
VanDeusen HR; Ramroop JR; Morel KL; Bae SY; Sheahan AV; Sychev Z; Lau NA; Cheng LC; Tan VM; Li Z; Petersen A; Lee JK; Park JW; Yang R; Hwang JH; Coleman I; Witte ON; Morrissey C; Corey E; Nelson PS; Ellis L; Drake JM
Mol Cancer Res; 2020 Aug; 18(8):1176-1188. PubMed ID: 32461304
[TBL] [Abstract] [Full Text] [Related]
12. Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review.
Gambardella C; Offi C; Clarizia G; Romano RM; Cozzolino I; Montella M; Di Crescenzo RM; Mascolo M; Cangiano A; Di Martino S; Candela G; Docimo G
BMC Endocr Disord; 2019 Oct; 19(1):103. PubMed ID: 31619220
[TBL] [Abstract] [Full Text] [Related]
13. A 9‑lncRNA risk score system for predicting the prognosis of patients with hepatitis B virus‑positive hepatocellular carcinoma.
Liu H; Zhao P; Jin X; Zhao Y; Chen Y; Yan T; Wang J; Wu L; Sun Y
Mol Med Rep; 2019 Jul; 20(1):573-583. PubMed ID: 31115573
[TBL] [Abstract] [Full Text] [Related]
14. Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type ret medullary thyroid cancer.
Sponziello M; Benvenuti S; Gentile A; Pecce V; Rosignolo F; Virzì AR; Milan M; Comoglio PM; Londin E; Fortina P; Barnabei A; Appetecchia M; Marandino F; Russo D; Filetti S; Durante C; Verrienti A
Hum Mutat; 2018 Mar; 39(3):371-377. PubMed ID: 29219214
[TBL] [Abstract] [Full Text] [Related]
15. Next-generation panel sequencing identifies
Gieldon L; Masjkur JR; Richter S; Därr R; Lahera M; Aust D; Zeugner S; Rump A; Hackmann K; Tzschach A; Januszewicz A; Prejbisz A; Eisenhofer G; Schrock E; Robledo M; Klink B
Eur J Endocrinol; 2018 Feb; 178(2):K1-K9. PubMed ID: 29158289
[TBL] [Abstract] [Full Text] [Related]
16. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.
Schöffski P; Gordon M; Smith DC; Kurzrock R; Daud A; Vogelzang NJ; Lee Y; Scheffold C; Shapiro GI
Eur J Cancer; 2017 Nov; 86():296-304. PubMed ID: 29059635
[TBL] [Abstract] [Full Text] [Related]
17. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review).
Katoh M
Int J Oncol; 2017 Nov; 51(5):1357-1369. PubMed ID: 29048660
[TBL] [Abstract] [Full Text] [Related]
18. Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors.
Reeser JW; Martin D; Miya J; Kautto EA; Lyon E; Zhu E; Wing MR; Smith A; Reeder M; Samorodnitsky E; Parks H; Naik KR; Gozgit J; Nowacki N; Davies KD; Varella-Garcia M; Yu L; Freud AG; Coleman J; Aisner DL; Roychowdhury S
J Mol Diagn; 2017 Sep; 19(5):682-696. PubMed ID: 28802831
[TBL] [Abstract] [Full Text] [Related]
19. Exercise overcome adverse effects among prostate cancer patients receiving androgen deprivation therapy: An update meta-analysis.
Yunfeng G; Weiyang H; Xueyang H; Yilong H; Xin G
Medicine (Baltimore); 2017 Jul; 96(27):e7368. PubMed ID: 28682886
[TBL] [Abstract] [Full Text] [Related]
20. Detection of Gene Rearrangements in Circulating Tumor Cells: Examples of ALK-, ROS1-, ret-Rearrangements in Non-Small-Cell Lung cancer and ERG-Rearrangements in prostate cancer.
Catelain C; Pailler E; Oulhen M; Faugeroux V; Pommier AL; Farace F
Adv Exp Med Biol; 2017; 994():169-179. PubMed ID: 28560674
[TBL] [Abstract] [Full Text] [Related]
[Next]
